Purpose: Holmium laser enucleation of the prostate can also be applied in the retreatment setting when other benign prostatic hyperplasia therapies fail. We compared outcomes in men who underwent holmium laser enucleation of the prostate in the primary vs the re-treatment setting. Materials and Methods: We retrospectively reviewed the records of 2,242 patients who underwent holmium laser enucleation of the prostate at a total of 4 academic hospitals between 2003 and 2015. Patient demographics, and operative and perioperative outcomes were compared between re-treatment and primary holmium laser enucleation of the prostate. Results: Of the 360 of 2,242 men (16%) who underwent re-treatment holmium laser enucleation of the prostate the procedure was done for residual urinary symptoms in 71%. The most common primary procedure was transurethral resection of the prostate in 42% of cases. Mean time between prior benign prostatic hyperplasia surgery and re-treatment was 68 months (range 1 to 444). There were no significant differences in age, prostate size, AUA (American Urological Association) symptom score or average flow rate between the cohorts. Perioperatively, re-treatment holmium laser enucleation of the prostate was associated with significantly shorter operative time, reduced blood loss, lower specimen weight and shorter length of stay. The AUA symptom score improved in both groups, although it remained higher in men who underwent re-treatment (6.5 vs 5.0, p <0.001). The likelihood of clot retention (4.7% vs 1.8%, p ¼ 0.01) and urethral stricture (3.3% vs 1.5%, p ¼ 0.043) was slightly higher in the re-treatment group.
See Editorial on page 1382.
Editor's Note: This article is the fifth of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 1582 and 1583. WHILE minimally invasive treatments for BPH can be effective in the appropriately selected patient, none of them are absolutely durable. As life expectancy increases, the need for reoperation for BPH increases. TURP has been considered the gold standard endoscopic procedure to treat BPH. Mostly based on anecdotal experience, patients are generally counseled that they may experience prostatic regrowth and need additional treatment 8 to 10 years following TURP. Re-treatment for BPH is done in 1% to 32% of men after various minimally invasive therapies. 1e5 HoLEP, which is performed as the primary treatment of BPH, is known to have a low re-treatment rate of around 1% to 3%. However, it is a potentially preferable surgical approach to the management of prostatic regrowth, given its ability to remove more tissue than other endoscopic approaches 6 and dissect along the true anatomical planes of BPH, similar to simple prostatectomy.
Some may assume that HoLEP in the re-treatment setting would be associated with more adverse outcomes and be more technically difficult compared to pHoLEP, although minimal evidence exists to support this. 7, 8 The aim of this series was to compare outcomes in men who underwent HoLEP in the primary vs the re-treatment setting.
MATERIALS AND METHODS
After obtaining institutional review board approval we retrospectively reviewed the charts of 2,242 men who underwent HoLEP between 2003 and 2015 at a total of 4 academic institutions, including Vanderbilt University Medical Center, Nashville, Tennessee; Indiana University School of Medicine, Indianapolis, Indiana; Mayo Clinic Minnesota, Rochester, Minnesota and Mayo Clinic Arizona, Scottsdale, Arizona. Men who had undergone prior BPH procedures regardless of type were placed in the rHoLEP cohort while those who had not undergone such procedures were placed in the pHoLEP cohort. For men undergoing rHoLEP the indication for re-treatment, and the date and type of the prior BPH procedure were captured.
For all patients demographic information was recorded, including patient age, BMI and ASA score. The voiding habits of the men were characterized prior to surgery by whether they were in urinary retention and by AUASS, Qmax, average urinary flow rate and PVR. Urinary flow rates were only included in analysis if voided volumes were 150 ml or greater. Prostate size was typically estimated on preoperative transrectal ultrasound, crosssectional imaging with computerized tomography or magnetic resonance imaging. The ellipsoid volume formula, volume ¼ length Â width Â height Â p/6, was used to calculate prostate volume. Urodynamics prior to HoLEP were performed at the discretion of the treating urologist.
Using the previously described technique standardized HoLEP was performed by 1 urologist each at Vanderbilt University Medical Center (NLM), Indiana Health University (JEL), Mayo Clinic Rochester (AEK) and Mayo Clinic Scottsdale (MRH). 9 Operative time, EBL, need for blood transfusion, resected tissue weight, pathological findings, intraoperative complications and LOS data were captured in the database.
Postoperative outcomes were assessed at the last available followup in the 3 to 12-month postoperative period. Outcomes reviewed included AUASS, Qmax, average urinary flow rate, PVR and postoperative complications. Urethral stricture, bladder neck contracture and new urinary incontinence were only assessed in men with at least 6 months of followup. This was done so that the rate of these complications would not be falsely decreased in men with shorter followup in whom there had perhaps not been enough time for these complications to develop. Similarly, because it sometimes takes several weeks or months for transient urinary incontinence to resolve, only men with 6 months or more of followup were considered.
Statistical analysis to compare patients treated with rHoLEP vs pHoLEP was performed with STATAÒ, version 11.
RESULTS
A total of 2,242 patients were included in the series, including 320 from Vanderbilt University Medical Center, 1,803 from Indiana Health University, 78 from Mayo Clinic Rochester and 41 from Mayo Clinic Arizona. Of these patients 360 (16%) had undergone prior BPH surgery. Mean time between prior treatment and rHoLEP was 68 months (range 1 to 444). When considering men who only underwent a single procedure before re-treatment, the average time to rHoLEP was 98.4 months for TURP, 49.4 months for laser surgery, 49.6 months for TUMT and 82.2 months for TUNA.
Four, 3, 2 and 1 prior BPH procedures were done in 4, 6, 51 and 299 men, respectively. The most common prior BPH surgery was TURP in 183 men (42%), followed by laser treatment in 123 (28%) and TUMT in 97 (22%) ( fig. 1 ). The indication for rHoLEP was known in 253 patients (70%) ( fig. 2 ). The most common reason for re-treatment was persistent LUTS in 179 cases (71%), followed by urinary retention in 63 (25%) and gross hematuria in 22 (9%).
Men treated with rHoLEP and pHoLEP were similar in age, BMI and ASA score (see table) . Preoperative AUASS results were similar in the retreatment and primary cohorts (20.5 vs 20.4, p ¼ 0.82). Estimated prostate size in those undergoing rHoLEP and pHoLEP was also similar at 98 and 102 cc, respectively (p ¼ 0.17).
Men undergoing re-treatment had significantly higher baseline maximum urinary flow (10.3 vs 9.0 ml per second, p ¼ 0.017) and lower PVR (204 vs 281 ml, p ¼ 0.0035) prior to HoLEP. Urodynamics were performed more often in men treated with rHoLEP (17% vs 6%, p ¼ 0.0001).
The table presents perioperative and postoperative outcomes. Men treated with rHoLEP had shorter operative time (86 vs 97 minutes, p ¼ 0.003), lower EBL (36 vs 80 ml), less enucleated tissue (69 vs 76 gm, p ¼ 0.023) and shorter LOS (1.1 vs 1.3 days, p ¼ 0.010). There was no difference between the 2 groups in regard to blood transfusion, the finding of cancer on final pathology or intraoperative complications. Postoperatively, there was significant improvement in AUASS in both groups, although more so in men treated with pHoLEP (5.0 vs 6.5, p <0.0001). Postoperative urinary flow rates and PVRs were similar in the 2 groups. Men who underwent rHoLEP were at higher risk for clot retention (4.7% vs 1.8%, p ¼ 0.01) and urethral stricture (3.3% vs 1.5%, p ¼ 0.043). There was no difference in the incidence of postoperative infection, bladder neck contracture or new incontinence between the 2 groups.
DISCUSSION
To our knowledge this is the largest series comparing men who underwent surgical re-treatment for BPH with HoLEP and men who underwent primary treatment. As life expectancy increases, not only will more men live long enough for symptomatic BPH to develop but some who undergo surgical intervention will require re-treatment. The re-treatment rate for BPH has been reported as 1% to 32% for various minimally invasive interventions. 1e4 In the current series the average time from prior BPH treatment to re-treatment was 5.7 years. TURP was durable for approximately 8 years compared to laser therapy and TUMT, which lasted for approximately 4 years in patients requiring re-treatment.
In men undergoing pHoLEP vs rHoLEP there was no difference in preoperative prostate volume (102 vs 98 cc, p ¼ 0.17). Unfortunately, prostate volume prior to initial BPH treatment was not available for review. Interestingly, when comparing prostate volume in men who had undergone 1 prior BPH procedure, there was no difference between those treated with TURP, laser therapy, TUMT or TUNA (p ¼ 0.46). The type of prior laser procedure performed as primary treatment was not known for all patients in the rHoLEP group.
While perhaps the patients who had undergone previous TURP had significant prostatic regrowth 8 years later, the nearly 100 cc average preoperative prostate volume 4 years following laser vaporization and TUMT suggests that these men were likely initially under treated. Patient selection may have led to a greater risk of failure and the need for secondary therapy or these men may have had multinodular BPH with accelerated de novo growth of BPH tissue necessitating re-treatment. Complaints of bothersome LUTS following prior BPH surgery require the urologist to distinguish between symptoms related to overactive bladder and symptoms of incomplete emptying due to an underactive bladder or outlet obstruction to facilitate appropriate treatment. In many cases men with a low urinary flow rate, elevated PVR and evidence of obstructive prostatic tissue on cystoscopy will benefit from BPH treatment and no further testing is required. However, prior to HoLEP in the current series men who required re-treatment had a significantly higher average maximum urinary flow rate (10.3 vs 9.0 ml per second, p ¼ 0.017) and a lower PVR (204 vs 281 ml, p ¼ 0.0035) than men who underwent primary BPH treatment.
Current guidelines recommend that before surgical intervention for BPH men with a maximum urinary flow rate greater than 10 ml per second should undergo pressure flow studies to confirm outlet obstruction. 10, 11 Correspondingly, urodynamics were more likely to be performed preoperatively in men who underwent rHoLEP (17% vs 6%, p ¼ 0.0001) to determine whether LUTS were secondary to obstruction and ensure that those in urinary retention had adequate detrusor function.
In the reoperative setting there is always concern that the initial procedure disrupted the natural tissue planes and may make subsequent surgical intervention more challenging. However, the current series and prior studies have failed to show this to be true for HoLEP. Elshal et al, 8 and Jaeger and Krambeck 7 commented that the plane of enucleation was identified without extra difficulty in their series of men undergoing rHoLEP. In the study by Elshal et al enucleation time was significantly shorter in men undergoing re-treatment than in those undergoing pHoLEP (76.0 vs 91.8 minutes, p ¼ 0.029). 8 However, preoperative prostate size was significantly smaller in the rHoLEP group (79.3 vs 94.3 cc, p ¼ 0.04) and significantly less tissue was removed (52.6 vs 64.5 cc, p ¼ 0.03), although enucleation rates appeared to be similar (1.50 vs 1.46 gm per minute).
In our experience most prior treatments tend to focus on the bladder neck and prostate floor, leaving the apical tissue almost untouched. This often facilitates correct identification of the plane between the peripheral and transition zones of the prostate to simplify rHoLEP. Others have reported similar operative times, including similar enucleation times and rates in a series of 37 men undergoing re-treatment compared to 74 undergoing pHoLEP matched based on prostate size. 7, 12 In the current series men who underwent re-treatment had overall shorter operative time (86 vs 97 minutes, p ¼ 0.003) in the setting of similar preoperative prostate volumes, although an average of 7 gm or less of tissue were resected in those undergoing rHoLEP (p ¼ 0.023).
The lower EBL noted in the rHoLEP arm (36 vs 80 cc, p ¼ 0.0001) is likely related to the shorter operative time and the fact that less tissue was resected. While the shorter operative time clearly demonstrates that rHoLEP is technically feasible, the faster time may also reflect more attending participation at these teaching institutions due to the possibility that HoLEP in a reoperative field would be more challenging for a trainee secondary to the altered prostate morphology and anatomy.
Men in the current series who underwent rHoLEP had excellent functional outcomes, similar to those in the pHoLEP arm and in other large series.
13e15 In terms of voiding parameters PVR improved in both groups by at least 150 ml and Qmax improved by more than 14 ml per second. Other large series of 230 to 1,000 men undergoing HoLEP showed a similar improvement in maximum urinary flow and PVR. 13, 15 All other groups who studied rHoLEP also found significantly improved and similar urinary flow rates and PVRs compared to men undergoing primary surgery. 7, 8, 12 In the current series AUASS improved significantly in the rHoLEP and pHoLEP arms, including to 6.5 from 20.5 (68% improvement) and to 5.0 from 20.4 (75% improvement), respectively. However, the postoperative AUASS was slightly higher in men treated with rHoLEP (p <0.0001). Men undergoing rHoLEP and pHoLEP in 2 prior series had a similar AUASS postoperatively, unlike in the current study. 8, 12 However, Jaeger and Krambeck noted a slightly higher AUASS in men who had undergone re-treatment (7.52 vs 5.21, p ¼ 0.0060). 7 The exact reason for this higher AUASS in men treated with rHoLEP in this series is unknown. However, an explanation may be that men who had undergone prior BPH surgery are more likely to have coexisting bladder dysfunction. Although the obstruction was relieved by HoLEP, as noted by the significant and similar improvement in peak urinary flow rates and PVRs, there may be baseline bladder dysfunction, leading to more irritative voiding symptoms. Regardless, men who underwent re-treatment had a significant improvement in symptomatology, which should be considered when counseling patients on rHoLEP despite the slightly higher overall score.
Re-treatment may be more prevalent with other minimally invasive treatment approaches compared to HoLEP because less BPH tissue is removed, especially as prostate size increases. With the increase in patient longevity and the advent of effective medical therapies delaying surgical intervention, prostates are now larger at the time of surgery. 16 HoLEP has previously been shown to have similar durable outcomes for larger glands, compared to simple prostatectomy, without a recurrence of BPH requiring re-treatment. 17, 18 Men undergoing rHoLEP experienced higher rates of postoperative clot retention (4.7% vs 1.8%, p ¼ 0.01) and urethral stricture (3.3% vs 1.5%, p ¼ 0.043). However, these rates are still quite low and they align with outcomes reported in other high volume HoLEP series.
19e21 The higher urethral stricture rate may be secondary to repeat instrumentation and the potential for scarring in the bulbar and penile urethra. There was no difference between rHoLEP and pHo-LEP in urinary tract infections, bladder neck contracture or new urinary incontinence postoperatively. Jaeger and Krambeck, 7 and Elshal et al 8 also found similar low rates of complications without any difference compared to men undergoing primary treatment. A statistical difference between the rates of postoperative clot retention and urethral stricture was likely detected in this series, given the much larger number of patients. The strengths of this study include its large size and its inclusion of multiple centers, making it more generalizable. While this study focused on HoLEP, at each institution a variety of surgical BPH solutions is offered, including monopolar and bipolar TURP, photovaporization of the prostate, transurethral incision of the prostate, button vaporization of the prostate, UroLiftÒ and simple prostatectomy. This study is limited by its retrospective nature as well as by the tertiary referral pattern of the included institutions. Many patients return to local urologists, which can limit followup and the attainment of prior records, such as prostate volume before the initial BPH surgery. Additionally, at all 4 centers the same validated questionnaires were not used to assess urinary incontinence, limiting the assessment of this postoperative condition.
CONCLUSIONS
The need for surgical re-treatment of BPH secondary to inadequate removal of tissue and prostatic regrowth will only increase as life expectancy increases. HoLEP after prior BPH procedures is not only technically feasible but also safe and effective, as demonstrated in this large multicenter series. Although there was a higher rate of postoperative clot retention and urethral stricture, the rate of these complications was still low and on par with those in other reported series of HoLEP.
